市場調査レポート

商品コード

1459813

血栓症治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年

Thrombosis Drugs Market (Drug Class: Factor Xa Inhibitor, Low Molecular Weight Heparin, P2Y12 Platelet Inhibitor, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日: 2024年02月14日
発行: Transparency Market Research
ページ情報: 英文 252 Pages
納期: 2～10営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 5,795 851,807円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,292,777円

レポートPDFを同一の部署内・課内の5名の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,733,747円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

血栓症治療薬市場- 調査範囲

TMRの血栓症治療薬の世界市場に関する調査レポートは、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界の血栓症治療薬市場の収益を提供しています。また、2023年から2031年までの世界の血栓症治療薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、血栓症治療薬市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照しました。

市場スナップショット
2022年の市場価値	291億米ドル
2031年の市場価値	515億米ドル
CAGR	6.7%

当レポートでは、世界の血栓症治療薬市場の競合情勢について調査しています。世界の血栓症治療薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の市場開拓、SWOTは、本レポートで紹介されている世界の血栓症治療薬市場におけるプレイヤーの属性です。

市場競合マトリックス（ティア別、企業規模別）
市場シェア分析：企業別（2022年）
企業プロファイル
- GSK plc
- Baxter International Inc.
- Johnson & Johnson
- Sanofi
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Bayer AG
- Aspen Pharmacare Holdings Limited
- Boehringer Ingelheim GmbH
- Pfizer, Inc.

図表

List of Tables

Table 01: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 02: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 03: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 07: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 08: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 11: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 12: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 15: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 16: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 19: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 20: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 23: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 24: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Thrombosis Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
Figure 02: Global Thrombosis Drugs Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global Thrombosis Drugs Market Value Share, by Drug Class, 2022
Figure 04: Global Thrombosis Drugs Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global Thrombosis Drugs Market Value Share, by Indication, 2022
Figure 06: Global Thrombosis Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Thrombosis Drugs Market Value Share, by Distribution Channel, 2022
Figure 08: Global Thrombosis Drugs Market Value Share, by Region, 2022
Figure 09: Global Thrombosis Drugs Market Value (US$ Mn) Forecast, 2023-2031
Figure 10: Global Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022-2031
Figure 11: Global Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 12: Global Thrombosis Drugs Market Value Share Analysis, by Indication, 2022-2031
Figure 13: Global Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 14: Global Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 15: Global Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global Thrombosis Drugs Market Value Share Analysis, by Region, 2022-2031
Figure 17: Global Thrombosis Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Thrombosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 19: North America Thrombosis Drugs Market Attractiveness Analysis, by Country, 2023-2031
Figure 20: North America Thrombosis Drugs Market Value Share Analysis, by Country, 2022-2031
Figure 21: North America Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022-2031
Figure 22: North America Thrombosis Drugs Market Value Share Analysis, by Indication, 2022-2031
Figure 23: North America Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 24: North America Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 25: North America Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 26: North America Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 27: Europe Thrombosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 28: Europe Thrombosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 29: Europe Thrombosis Drugs Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 30: Europe Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022-2031
Figure 31: Europe Thrombosis Drugs Market Value Share Analysis, by Indication, 2022-2031
Figure 32: Europe Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 33: Europe Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 34: Europe Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 35: Europe Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 36: Asia Pacific Thrombosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 37: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 39: Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022-2031
Figure 40: Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Indication, 2022-2031
Figure 41: Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 42: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 43: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 44: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 45: Latin America Thrombosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 46: Latin America Thrombosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 47: Latin America Thrombosis Drugs Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 48: Latin America Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022-2031
Figure 49: Latin America Thrombosis Drugs Market Value Share Analysis, by Indication, 2022-2031
Figure 50: Latin America Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 51: Latin America Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 52: Latin America Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 53: Latin America Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 54: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 55: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 56: Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 57: Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022-2031
Figure 58: Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Indication, 2022-2031
Figure 59: Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 60: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 61: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 62: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Product Code: TMRGL46293

Thrombosis Drugs Market - Scope of Report

TMR's report on the global thrombosis drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global thrombosis drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global thrombosis drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the thrombosis drugs market.

Market Snapshot
Market Value in 2022	US$ 29.1 Bn
Market Value in 2031	US$ 51.5 Bn
CAGR	6.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global thrombosis drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global thrombosis drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global thrombosis drugs market.

The report delves into the competitive landscape of the global thrombosis drugs market. Key players operating in the global thrombosis drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global thrombosis drugs market profiled in this report.

Key Questions Answered in Global thrombosis drugs Market Report:

What is the sales/revenue generated by thrombosis drugs across all regions during the forecast period?
What are the opportunities in the global thrombosis drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Thrombosis Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global thrombosis drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global thrombosis drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global thrombosis drugs market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Thrombosis Drugs Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Thrombosis Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Thrombosis Drugs Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
- 6.3.1. Factor Xa Inhibitor
- 6.3.2. Low Molecular Weight Heparin
- 6.3.3. P2Y12 Platelet Inhibitor
- 6.3.4. Others
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Thrombosis Drugs Market Analysis and Forecast, by Indication

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017-2031
- 7.3.1. Pulmonary Embolism
- 7.3.2. Atrial Fibrillation
- 7.3.3. Deep Vein Thrombosis
- 7.3.4. Others
7.4. Market Attractiveness Analysis, by Indication

8. Global Thrombosis Drugs Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Thrombosis Drugs Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Thrombosis Drugs Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017-2031
- 10.3.1. Factor Xa Inhibitor
- 10.3.2. Low Molecular Weight Heparin
- 10.3.3. P2Y12 Platelet Inhibitor
- 10.3.4. Others
10.4. Market Value Forecast, by Indication, 2017-2031
- 10.4.1. Pulmonary Embolism
- 10.4.2. Atrial Fibrillation
- 10.4.3. Deep Vein Thrombosis
- 10.4.4. Others
10.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017-2031
- 10.6.1. U.S.
- 10.6.2. Canada
10.7. Market Attractiveness Analysis
- 10.7.1. By Drug Class
- 10.7.2. By Indication
- 10.7.3. By Distribution Channel
- 10.7.4. By Country

11. Europe Thrombosis Drugs Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017-2031
- 11.3.1. Factor Xa Inhibitor
- 11.3.2. Low Molecular Weight Heparin
- 11.3.3. P2Y12 Platelet Inhibitor
- 11.3.4. Others
11.4. Market Value Forecast, by Indication, 2017-2031
- 11.4.1. Pulmonary Embolism
- 11.4.2. Atrial Fibrillation
- 11.4.3. Deep Vein Thrombosis
- 11.4.4. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.5.1. Hospital Pharmacies
- 11.5.2. Retail Pharmacies
- 11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
- 11.7.1. By Drug Class
- 11.7.2. By Indication
- 11.7.3. By Distribution Channel
- 11.7.4. By Country/Sub-region

12. Asia Pacific Thrombosis Drugs Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017-2031
- 12.3.1. Factor Xa Inhibitor
- 12.3.2. Low Molecular Weight Heparin
- 12.3.3. P2Y12 Platelet Inhibitor
- 12.3.4. Others
12.4. Market Value Forecast, by Indication, 2017-2031
- 12.4.1. Pulmonary Embolism
- 12.4.2. Atrial Fibrillation
- 12.4.3. Deep Vein Thrombosis
- 12.4.4. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.5.1. Hospital Pharmacies
- 12.5.2. Retail Pharmacies
- 12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
- 12.7.1. By Drug Class
- 12.7.2. By Indication
- 12.7.3. By Distribution Channel
- 12.7.4. By Country/Sub-region

13. Latin America Thrombosis Drugs Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017-2031
- 13.3.1. Factor Xa Inhibitor
- 13.3.2. Low Molecular Weight Heparin
- 13.3.3. P2Y12 Platelet Inhibitor
- 13.3.4. Others
13.4. Market Value Forecast, by Indication, 2017-2031
- 13.4.1. Pulmonary Embolism
- 13.4.2. Atrial Fibrillation
- 13.4.3. Deep Vein Thrombosis
- 13.4.4. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.5.1. Hospital Pharmacies
- 13.5.2. Retail Pharmacies
- 13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
- 13.7.1. By Drug Class
- 13.7.2. By Indication
- 13.7.3. By Distribution Channel
- 13.7.4. By Country/Sub-region

14. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast

14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017-2031
- 14.3.1. Factor Xa Inhibitor
- 14.3.2. Low Molecular Weight Heparin
- 14.3.3. P2Y12 Platelet Inhibitor
- 14.3.4. Others
14.4. Market Value Forecast, by Indication, 2017-2031
- 14.4.1. Pulmonary Embolism
- 14.4.2. Atrial Fibrillation
- 14.4.3. Deep Vein Thrombosis
- 14.4.4. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.5.1. Hospital Pharmacies
- 14.5.2. Retail Pharmacies
- 14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
- 14.7.1. By Drug Class
- 14.7.2. By Indication
- 14.7.3. By Distribution Channel
- 14.7.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
- 15.3.1. GSK plc
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. SWOT Analysis
  - 15.3.1.4. Financial Overview
  - 15.3.1.5. Strategic Overview
- 15.3.2. Baxter International Inc.
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. SWOT Analysis
  - 15.3.2.4. Financial Overview
  - 15.3.2.5. Strategic Overview
- 15.3.3. Johnson & Johnson
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. SWOT Analysis
  - 15.3.3.4. Financial Overview
  - 15.3.3.5. Strategic Overview
- 15.3.4. Sanofi
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. SWOT Analysis
  - 15.3.4.4. Financial Overview
  - 15.3.4.5. Strategic Overview
- 15.3.5. Bristol-Myers Squibb Company
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. SWOT Analysis
  - 15.3.5.4. Financial Overview
  - 15.3.5.5. Strategic Overview
- 15.3.6. AstraZeneca plc
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. SWOT Analysis
  - 15.3.6.4. Financial Overview
  - 15.3.6.5. Strategic Overview
- 15.3.7. Bayer AG
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. SWOT Analysis
  - 15.3.7.4. Financial Overview
  - 15.3.7.5. Strategic Overview
- 15.3.8. Aspen Pharmacare Holdings Limited
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. SWOT Analysis
  - 15.3.8.4. Financial Overview
  - 15.3.8.5. Strategic Overview
- 15.3.9. Boehringer Ingelheim GmbH
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. SWOT Analysis
  - 15.3.9.4. Financial Overview
  - 15.3.9.5. Strategic Overview
- 15.3.10. Pfizer, Inc.
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Product Portfolio
  - 15.3.10.3. SWOT Analysis
  - 15.3.10.4. Financial Overview
  - 15.3.10.5. Strategic Overview

血栓症治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年

Thrombosis Drugs Market (Drug Class: Factor Xa Inhibitor, Low Molecular Weight Heparin, P2Y12 Platelet Inhibitor, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

血栓症治療薬市場- 調査範囲

目次

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界市場

第4章市場概要

第5章主要洞察

第6章世界市場分析と予測：薬剤クラス別

第7章世界市場分析と予測：適応症別

第8章世界市場分析と予測：流通チャネル別

第9章世界市場分析と予測：地域別

第10章北米市場分析と予測

第11章欧州市場分析と予測

第12章アジア太平洋市場分析と予測

第13章ラテンアメリカ市場分析と予測

第14章中東・アフリカ市場分析と予測

第15章競合情勢

List of Tables

List of Figures

Thrombosis Drugs Market - Scope of Report

Key Questions Answered in Global thrombosis drugs Market Report:

Thrombosis Drugs Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Thrombosis Drugs Market

4. Market Overview

5. Key Insights

6. Global Thrombosis Drugs Market Analysis and Forecast, by Drug Class

7. Global Thrombosis Drugs Market Analysis and Forecast, by Indication

8. Global Thrombosis Drugs Market Analysis and Forecast, by Distribution Channel

9. Global Thrombosis Drugs Market Analysis and Forecast, by Region

10. North America Thrombosis Drugs Market Analysis and Forecast

11. Europe Thrombosis Drugs Market Analysis and Forecast

12. Asia Pacific Thrombosis Drugs Market Analysis and Forecast

13. Latin America Thrombosis Drugs Market Analysis and Forecast

14. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast

15. Competition Landscape

血栓症治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年

Thrombosis Drugs Market (Drug Class: Factor Xa Inhibitor, Low Molecular Weight Heparin, P2Y12 Platelet Inhibitor, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

血栓症治療薬市場- 調査範囲

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

第5章 主要洞察

第6章 世界市場分析と予測：薬剤クラス別

第7章 世界市場分析と予測：適応症別

第8章 世界市場分析と予測：流通チャネル別

第9章 世界市場分析と予測：地域別

第10章 北米市場分析と予測

第11章 欧州市場分析と予測

第12章 アジア太平洋市場分析と予測

第13章 ラテンアメリカ市場分析と予測

第14章 中東・アフリカ市場分析と予測

第15章 競合情勢

List of Tables

List of Figures

Thrombosis Drugs Market - Scope of Report

Key Questions Answered in Global thrombosis drugs Market Report:

Thrombosis Drugs Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Thrombosis Drugs Market

4. Market Overview

5. Key Insights

6. Global Thrombosis Drugs Market Analysis and Forecast, by Drug Class

7. Global Thrombosis Drugs Market Analysis and Forecast, by Indication

8. Global Thrombosis Drugs Market Analysis and Forecast, by Distribution Channel

9. Global Thrombosis Drugs Market Analysis and Forecast, by Region

10. North America Thrombosis Drugs Market Analysis and Forecast

11. Europe Thrombosis Drugs Market Analysis and Forecast

12. Asia Pacific Thrombosis Drugs Market Analysis and Forecast

13. Latin America Thrombosis Drugs Market Analysis and Forecast

14. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast

15. Competition Landscape

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界市場

第4章市場概要

第5章主要洞察

第6章世界市場分析と予測：薬剤クラス別

第7章世界市場分析と予測：適応症別

第8章世界市場分析と予測：流通チャネル別

第9章世界市場分析と予測：地域別

第10章北米市場分析と予測

第11章欧州市場分析と予測

第12章アジア太平洋市場分析と予測

第13章ラテンアメリカ市場分析と予測

第14章中東・アフリカ市場分析と予測

第15章競合情勢